In pursuance of the order of the Government of the Russian Federation dated November 25, 2020 No. 3100-r on the provision of emergency medical care to a limited population of patients with especially severe pathology, on December 21, 2020 the Federal State Unitary Enterprise “Moscow Endocrine Plant” - ENDOPHARM, which is subordinate to the Ministry of Industry and Trade of Russia, carried out the import of 2,500 packs of a medicinal product not registered in the Russian Federation with the INN “Melphalan” (lyophilisate for preparing a solution for intravascular administration, complete with a solvent).
The drug "Melphalan" belongs to the pharmacotherapeutic group of antineoplastic agents, alkylating compounds and is used to treat cancer patients with multiple myeloma, progressive ovarian cancer, and polycythemia vera.
By the end of the year, the Federal State Unitary Enterprise “Moscow Endocrine Plant”, in accordance with the established procedure, will fully transfer the drug “Melphalan” to medical institutions determined by the Ministry of Health of Russia.
Comment type is not specified in the component properties.